Collaborations Pharmaceuticals, Inc.

Collaborations Pharmaceuticals, Inc. is a biotechnology research company that integrates artificial intelligence (AI) software with drug discovery to address rare and neglected infectious diseases. Founded in 2015, the firm develops machine learning models and software platforms to identify novel molecules, repurpose existing drugs, assess toxicology, and design chemical compounds with specific properties. This technology is applied internally to build a pipeline of therapeutic candidates and is also offered to external partners, including pharmaceutical, consumer product, and agrochemical companies, through licensing and fee-for-service arrangements.

The company's dual focus on software development and therapeutic pipeline creation allows it to fund research through diversified revenue streams while advancing clinical assets. Its work is supported by significant funding from the National Institutes of Health (NIH) and the Department of Defense. The firm actively engages in partnerships to manufacture and translate preclinical assets, such as its recombinant human enzyme replacement therapy for CLN1 disease, which has received orphan drug and rare pediatric disease designations. By combining decades of drug discovery expertise with computational tools, the company solves complex chemistry and biology challenges for its clients and collaborators across the global biotech and life sciences sectors.